JP2019510735A5 - - Google Patents

Download PDF

Info

Publication number
JP2019510735A5
JP2019510735A5 JP2018535367A JP2018535367A JP2019510735A5 JP 2019510735 A5 JP2019510735 A5 JP 2019510735A5 JP 2018535367 A JP2018535367 A JP 2018535367A JP 2018535367 A JP2018535367 A JP 2018535367A JP 2019510735 A5 JP2019510735 A5 JP 2019510735A5
Authority
JP
Japan
Prior art keywords
prodrug
dysplasia
syndrome
cnp
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018535367A
Other languages
English (en)
Japanese (ja)
Other versions
JP6968802B2 (ja
JP2019510735A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2017/050209 external-priority patent/WO2017118698A1/en
Publication of JP2019510735A publication Critical patent/JP2019510735A/ja
Publication of JP2019510735A5 publication Critical patent/JP2019510735A5/ja
Priority to JP2021175180A priority Critical patent/JP7816947B2/ja
Application granted granted Critical
Publication of JP6968802B2 publication Critical patent/JP6968802B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018535367A 2016-01-08 2017-01-05 環部分にキャリア結合を有するｃｎｐプロドラッグ Active JP6968802B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021175180A JP7816947B2 (ja) 2016-01-08 2021-10-27 環部分にキャリア結合を有するｃｎｐプロドラッグ

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP16150625.8 2016-01-08
EP16150625 2016-01-08
EP16179288.2 2016-07-13
EP16179288 2016-07-13
EP16191460 2016-09-29
EP16191460.1 2016-09-29
PCT/EP2017/050209 WO2017118698A1 (en) 2016-01-08 2017-01-05 Cnp prodrugs with carrier attachment at the ring moiety

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021175180A Division JP7816947B2 (ja) 2016-01-08 2021-10-27 環部分にキャリア結合を有するｃｎｐプロドラッグ

Publications (3)

Publication Number Publication Date
JP2019510735A JP2019510735A (ja) 2019-04-18
JP2019510735A5 true JP2019510735A5 (https=) 2019-12-19
JP6968802B2 JP6968802B2 (ja) 2021-11-17

Family

ID=57821955

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018535367A Active JP6968802B2 (ja) 2016-01-08 2017-01-05 環部分にキャリア結合を有するｃｎｐプロドラッグ
JP2021175180A Active JP7816947B2 (ja) 2016-01-08 2021-10-27 環部分にキャリア結合を有するｃｎｐプロドラッグ

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021175180A Active JP7816947B2 (ja) 2016-01-08 2021-10-27 環部分にキャリア結合を有するｃｎｐプロドラッグ

Country Status (16)

Country Link
US (3) US11413351B2 (https=)
EP (2) EP3400019B1 (https=)
JP (2) JP6968802B2 (https=)
AU (4) AU2017205688C1 (https=)
CA (1) CA3007979C (https=)
DK (1) DK3400019T3 (https=)
ES (1) ES2934582T3 (https=)
HR (1) HRP20221339T1 (https=)
HU (1) HUE060521T2 (https=)
LT (1) LT3400019T (https=)
PL (1) PL3400019T3 (https=)
RS (1) RS63793B1 (https=)
SI (1) SI3400019T1 (https=)
SM (1) SMT202200466T1 (https=)
WO (1) WO2017118698A1 (https=)
ZA (1) ZA201804415B (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3400019T (lt) 2016-01-08 2022-12-12 Ascendis Pharma Growth Disorders A/S Cnp provaistai su prie žiedo fragmento prijungtu nešikliu
MX2018008061A (es) 2016-01-08 2018-08-23 Ascendis Pharma Growth Disorders As Profarmacos de peptido natriuretico tipo c (cnp) con porciones portadoras grandes.
IL297375B2 (en) * 2016-01-08 2024-02-01 Ascendis Pharma Growth Disorders As Controlled-release CNP agonists with low NPR–C binding
NZ743487A (en) 2016-01-08 2023-02-24 Ascendis Pharma Growth Disorders As Controlled-release cnp agonists with increased nep stability
IL259827B2 (en) 2016-01-08 2025-07-01 Ascendis Pharma Growth Disorders As Controlled-release CNP agonists with low initial NPR-B activity
WO2017118707A1 (en) 2016-01-08 2017-07-13 Ascendis Pharma Growth Disorders A/S Controlled-release cnp agonists with reduced side-effects
HUE062117T2 (hu) 2016-09-29 2023-09-28 Ascendis Pharma Growth Disorders As Kombinációs terápia szabályozott felszabadulású CNP agonistákkal
EP4011396A1 (en) 2017-03-10 2022-06-15 QuiaPEG Pharmaceuticals AB Releasable conjugates
AU2019340472A1 (en) 2018-09-12 2021-04-01 Quiapeg Pharmaceuticals Ab Releasable GLP-1 conjugates
EP3923906A1 (en) 2019-02-11 2021-12-22 Ascendis Pharma Growth Disorders A/S Dry pharmaceutical formulations of cnp conjugates
BR112022004697A2 (pt) * 2019-09-16 2022-06-14 Biomarin Pharm Inc Variantes de cnp e conjugados das mesmas
WO2022115563A1 (en) * 2020-11-25 2022-06-02 Prolynx Llc Extended release hydrogel conjugates of c-natriuretic peptides
IL316466A (en) 2022-05-23 2024-12-01 Ascendis Pharma Growth Disorders As Liquid pharmaceutical formulations of cnp compounds
EP4612167A1 (en) 2022-11-02 2025-09-10 Novo Nordisk A/S Cnp compounds

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2226575C (en) 1995-07-27 2011-10-18 Genentech, Inc. Stabile isotonic lyophilized protein formulation
US6624142B2 (en) 1997-12-30 2003-09-23 Enzon, Inc. Trimethyl lock based tetrapartate prodrugs
CN1169573C (zh) 1998-09-28 2004-10-06 参天制药株式会社 用于治疗角结膜障碍的、包含作为活性组分的钠尿肽的泪液分泌促进剂或滴眼剂
AR024558A1 (es) 1999-06-01 2002-10-16 Neuralab Ltd Composiciones del peptido a-beta y procesos para producir las mismas
BRPI0203172B8 (pt) 2001-09-28 2021-05-25 Nakao Kazuwa composição farmacêutica para acondroplasia
EP2042196B1 (en) 2001-10-10 2016-07-13 ratiopharm GmbH Remodelling and glycoconjugation of Granulocyte Colony Stimulating Factor (G-CSF)
US7122189B2 (en) 2002-08-13 2006-10-17 Enzon, Inc. Releasable polymeric conjugates based on aliphatic biodegradable linkers
AU2003297583B2 (en) 2002-11-26 2010-01-14 Biocon, Ltd Modified naturetic compounds, conjugates, and uses thereof
US7332164B2 (en) 2003-03-21 2008-02-19 Enzon Pharmaceuticals, Inc. Heterobifunctional polymeric bioconjugates
CA2521784C (en) 2003-04-08 2012-03-27 Yeda Research And Development Co. Ltd. Reversible pegylated drugs
CA2763817C (en) 2003-04-08 2014-05-27 Yeda Research And Development Co. Ltd. Reversible pegylated drugs
MXPA06010782A (es) 2004-03-23 2007-03-28 Complex Biosystems Gmbh Ligador de profarmaco.
GB2427360A (en) 2005-06-22 2006-12-27 Complex Biosystems Gmbh Aliphatic prodrug linker
CU23556A1 (es) 2005-11-30 2010-07-20 Ct Ingenieria Genetica Biotech Estructura polimérica semejante a dendrímero para la obtención de conjugados de interés farmacéutico
US8450269B2 (en) 2006-02-03 2013-05-28 Prolor Biotech Ltd. Long-acting growth hormone and methods of producing same
US9283260B2 (en) 2006-04-21 2016-03-15 Amgen Inc. Lyophilized therapeutic peptibody formulations
JP2010502231A (ja) 2006-09-08 2010-01-28 メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ 血管拡張作用を欠く水利尿およびナトリウム利尿ポリペプチド
JP2010503707A (ja) 2006-09-15 2010-02-04 エンゾン ファーマスーティカルズ インコーポレイテッド オリゴヌクレオチドの送達を目的としたヒンダードエステル系生体分解性リンカー
TWI409081B (zh) 2006-11-09 2013-09-21 Alcon Res Ltd 用於藥物輸送之水不溶性聚合物基質
CA2681567C (en) 2007-03-22 2016-07-19 The Regents Of The University Of Colorado, A Body Corporate Method of preparing an immunologically-active adjuvant-bound dried vaccine composition
KR20080098216A (ko) 2007-05-04 2008-11-07 한미약품 주식회사 캐리어 물질을 이용한 나트륨 배설 펩타이드 약물 결합체
ATE502114T1 (de) 2007-06-21 2011-04-15 Univ Muenchen Tech Biologisch aktive proteine mit erhöhter in-vivo- und/oder in-vitro-stabilität
TW200922624A (en) 2007-07-11 2009-06-01 Enzon Pharmaceuticals Inc Polymeric drug delivery system containing a multi-substituted aromatic moiety
AR069409A1 (es) * 2007-11-21 2010-01-20 Biomarin Pharm Inc Variantes de peptidos natriureticos de tipo c
AU2008340304B2 (en) 2007-12-21 2016-03-03 Aptevo Biotherapeutics Llc Stabilized factor IX formulations containing trehalose
MX2010008024A (es) 2008-02-01 2010-12-21 Ascendis Pharma As Profarmaco que comprende un enlazador que se puede separar por si mismo.
TW201004648A (en) 2008-05-23 2010-02-01 Enzon Pharmaceuticals Inc Polymeric systems containing intracellular releasable disulfide linker for the delivery of oligonucleotides
CN101809029B (zh) * 2008-05-23 2016-06-15 第一三共株式会社 具有延长目标肽的血浆半衰期作用的肽
WO2009156481A1 (en) 2008-06-25 2009-12-30 Ascendis Pharma As Pegylated bnp
WO2010033216A1 (en) 2008-09-19 2010-03-25 Nektar Therapeutics Polymer conjugates of nesiritide peptides
CA2748314C (en) 2009-02-03 2018-10-02 Amunix Operating Inc. Extended recombinant polypeptides and compositions comprising same
ES2608457T3 (es) 2009-05-20 2017-04-11 Biomarin Pharmaceutical Inc. Variantes de péptido natriurético de tipo C
EP2459227B1 (en) 2009-07-31 2021-03-17 Ascendis Pharma A/S Prodrugs containing an aromatic amine connected by an amide bond to a carrier
WO2011031441A1 (en) 2009-08-28 2011-03-17 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Therapy with a chimeric molecule and a pro-apoptotic agent
CA2783296C (en) 2009-12-15 2019-01-15 Ascendis Pharma As Growth hormone composition
WO2011075471A2 (en) 2009-12-18 2011-06-23 Alcon Research, Ltd. Novel npr-b agonists and methods of use for the treatment of c-type natriuretic peptide-mediated disorders
CN102724967A (zh) 2009-12-31 2012-10-10 安龙制药公司 包括可释放的脲连接体的含芳香胺化合物的聚合缀合物
WO2011089214A1 (en) 2010-01-22 2011-07-28 Ascendis Pharma As Carrier-linked carbamate prodrug linkers
WO2011089215A1 (en) 2010-01-22 2011-07-28 Ascendis Pharma As Dipeptide-based prodrug linkers for aromatic amine-containing drugs
EP2525830B1 (en) 2010-01-22 2016-05-11 Ascendis Pharma A/S Dipeptide-based prodrug linkers for aliphatic amine-containing drugs
EP2552967A4 (en) 2010-04-02 2014-10-08 Amunix Operating Inc BINDING FUSION PROTEINS, BINDING FUSION PROTEIN MEDICINAL CONJUGATES, XTEN MEDICAMENT CONJUGATES, AND METHOD FOR THEIR PREPARATION AND USE
EP2566334B1 (en) 2010-05-05 2018-04-18 Prolynx, LLC Controlled drug release from solid supports
EP2566335B1 (en) 2010-05-05 2016-06-29 Prolynx Llc Controlled release of active compounds from macromolecular conjugates
WO2011144756A1 (en) 2010-05-21 2011-11-24 Xl-Protein Gmbh Biosynthetic proline/alanine random coil polypeptides and their uses
AU2012296951B2 (en) 2011-08-12 2016-09-15 Ascendis Pharma A/S Protein carrier-linked prodrugs
HK1198913A1 (en) 2011-08-12 2015-06-19 Ascendis Pharma A/S Carrier-linked prodrugs having reversible carboxylic ester linkages
WO2013024047A1 (en) 2011-08-12 2013-02-21 Ascendis Pharma A/S High-loading water-soluble carrier-linked prodrugs
AU2012296950B2 (en) 2011-08-12 2016-09-22 Ascendis Pharma A/S Polymeric hyperbranched carrier-linked prodrugs
MX349950B (es) 2011-08-12 2017-08-22 Ascendis Pharma As Profarmacos de treprostinil enlazados a un portador.
WO2013036857A1 (en) 2011-09-07 2013-03-14 Prolynx Llc Sulfone linkers
JPWO2013161895A1 (ja) 2012-04-25 2015-12-24 第一三共株式会社 骨修復促進剤
US20150087688A1 (en) 2012-04-25 2015-03-26 Ascendis Pharma A/S Prodrugs of hydroxyl-comprising drugs
US10052366B2 (en) 2012-05-21 2018-08-21 Alexion Pharmaceuticsl, Inc. Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
JP6536871B2 (ja) 2013-12-02 2019-07-03 国立大学法人京都大学 Ｆｇｆｒ３病の予防および治療剤ならびにそのスクリーニング方法
KR20160118264A (ko) 2014-02-27 2016-10-11 다이이찌 산쿄 가부시키가이샤 스테로이드제 투여로 유발되는 성장 장해에 대한 의약
US11547743B2 (en) 2014-04-28 2023-01-10 Eisai R&D Management Co., Ltd. Lyophilized formulation of HGF
CA2955569C (en) 2014-08-06 2023-02-14 Ascendis Pharma A/S Prodrugs comprising an aminoalkyl glycine linker
EP3242689A1 (en) 2015-01-09 2017-11-15 Ascendis Pharma Growth Disorders A/S Cnp prodrugs
KR20260046164A (ko) 2015-07-30 2026-04-06 바이오마린 파머수티컬 인크. 골 이형성증 치료를 위한 c―형 나트륨이뇨 펩타이드 변이체의 용도
PL3386531T3 (pl) 2015-12-08 2022-02-28 Biomarin Pharmaceutical Inc. Zastosowanie wariantów peptydu natriuretycznego typu c w leczeniu choroby zwyrodnieniowej stawów
LT3400019T (lt) 2016-01-08 2022-12-12 Ascendis Pharma Growth Disorders A/S Cnp provaistai su prie žiedo fragmento prijungtu nešikliu
WO2017118707A1 (en) 2016-01-08 2017-07-13 Ascendis Pharma Growth Disorders A/S Controlled-release cnp agonists with reduced side-effects
IL259827B2 (en) 2016-01-08 2025-07-01 Ascendis Pharma Growth Disorders As Controlled-release CNP agonists with low initial NPR-B activity
MX2018008061A (es) 2016-01-08 2018-08-23 Ascendis Pharma Growth Disorders As Profarmacos de peptido natriuretico tipo c (cnp) con porciones portadoras grandes.
IL297375B2 (en) 2016-01-08 2024-02-01 Ascendis Pharma Growth Disorders As Controlled-release CNP agonists with low NPR–C binding
NZ743487A (en) 2016-01-08 2023-02-24 Ascendis Pharma Growth Disorders As Controlled-release cnp agonists with increased nep stability
HUE062117T2 (hu) 2016-09-29 2023-09-28 Ascendis Pharma Growth Disorders As Kombinációs terápia szabályozott felszabadulású CNP agonistákkal
CA3109223A1 (en) 2018-08-16 2020-02-20 Beyondspring Pharmaceuticals, Inc. Method and composition for stimulating immune response
EP3923906A1 (en) 2019-02-11 2021-12-22 Ascendis Pharma Growth Disorders A/S Dry pharmaceutical formulations of cnp conjugates

Similar Documents

Publication Publication Date Title
JP2019510735A5 (https=)
JP2019507724A5 (https=)
JP2019507725A5 (https=)
JP7692454B2 (ja) 大型のキャリアー部分を有するｃｎｐプロドラッグ
JP7714087B2 (ja) 増加したｎｅｐ安定性を有する徐放ｃｎｐ作動薬
JP7816947B2 (ja) 環部分にキャリア結合を有するｃｎｐプロドラッグ
US20210069339A1 (en) Cnp prodrugs
CN103596584A (zh) 多取代的胰岛素
CA3064320A1 (en) Mic-1 compounds and uses thereof
CN105148289B (zh) 一种两亲性寡聚多肽药物结合物
CN120641434A (zh) 人类运铁蛋白受体结合肽
HK1246666A1 (zh) Cnp前药
HK1246666B (en) Cnp prodrugs